Introduction
practice however, measurement of serum creatinine is the most widely used marker of renal function, which The assessment of progression in chronic renal diseases can be assessed at a low cost and with little inconveniis important to monitor the development of renal ence for the patient. insufficiency in individuals, to evaluate the importance There are however several problems related to the of putative progression promoters in observational use of serum creatinine as a marker of renal function studies, and to evaluate the effectiveness of treatment as reviewed by Levey [7] . Firstly there are technical on progression in clinical trials. The rate of progression difficulties with interfering substances (glucose, in renal function has been considered a primary end ketones) which can be solved by the use of a reaction point in clinical trials like time to development of end kinetic principle. Secondly the level of serum creatinine stage renal disease or death. Usually progression is is not only dependent on the GFR: creatinine does not evaluated by repeated measurements of markers of behave like an ideal filtration marker, there is tubular renal function. The progression can be assessed as the secretion, which changes with variation in GFR [5], rate of change in the marker, or as the time to an and is affected by several drugs (e.g. cimetidine salicylendpoint such as a certain degree of impairment in ates and trimethoprim). There is extrarenal elimination renal function [1] . The time to doubling of baseline particularly in patients with low GFR. Furthermore serum creatinine is such an example, which have been the generation of creatinine is influenced by changes applied in several recent large, completed or ongoing, in muscle mass and dietary intake of protein. These clinical trials evaluating the effect of different treatment conditions make it difficult to use serum creatinine to modalities on the progression of chronic renal diseases correctly estimate the level of renal function. In patients [2] [3] [4] . As several studies have suggested serum creatinwith declining renal function there is an increase in ine to be a poor marker of renal function [5] , it seems fractional tubular secretion and extrarenal elimination. appropriate to consider the sensitivity and relevance
Usually there is a lowering in muscle mass and often of doubling of serum creatinine as a trial endpoint. a restriction in protein intake. All of which will tend to preserve the level of serum creatinine, despite declining GFR. Accordingly Shemes et al. [5] Serum creatinine as a marker of renal function found that patients with a GFR as low as 30 ml/min/1.73m2 may have normal serum creatinThe renal clearance of inulin during constant infusion ine, and in their follow-up study [5] a 50% reduction has been considered the gold standard for determinain GFR was only associated with an average increase tion of glomerular filtration rate (GFR), but the cumof 64% in serum creatinine, and even a lack of increase bersome procedures, difficulties with measuring inulin in some patients, thus an increase in serum creatinine and limited availability has encouraged the search for is not a very sensitive measurement of renal function. alternatives. The radioisotope-labelled markers [125I ]-This is in particular the case in patients with normal lothalamate, [99mTc]-DTPA and [51Cr]-EDTA have renal function due to the flat relationship between been found to give accurate and precise estimates of serum creatinine and GFR. On the other hand this GFR [1] , whether using renal or plasma clearance endpoint is very specific, because a doubling of serum techniques [6 ] . The latter method avoids problems creatinine reflects a true decline in renal function unless with incomplete urine collections, a frequent phenomit is due to change in therapy or diet.
In studies of the effect of low protein diet the effect Correspondence and offprint requests to: Dr Peter Rossing, Steno of the intervention on renal creatinine handling invalidDiabetes Centre, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark.
ates serum creatinine as a measurement of renal func-tion. The Modification of Diet in Renal Disease study the endpoint. It has been suggested that at least 70% of the patients have to reach the endpoint in order to [8] concluded that while a significant beneficial effect of low protein diet could not be demonstrated when allow proper evaluation [10] .
Is it then relevant to use doubling of serum creatinine using a true marker of GFR, such an effect would erroneously have been found if creatinine data had as an endpoint in clinical trials? As previously discussed this endpoint is not very sensitive, but rather specific been used [9] .
if it is demonstrated that the applied intervention is not interfering with the analysis of creatinine (i.e.
Doubling of serum creatinine for the assessment of
cephalosporins) or affecting the serum creatinine levels progression by interference with metabolism and renal handling of creatinine (i.e. low protein diet, and medication such as cimetidine). Furthermore the groups to be compared Despite the above mentioned limitations of serum creatinine as a marker of renal function it has been should be well matched not only regarding the level of serum creatinine but also factors determining the renal used in numerous studies, either using the slope of 1/serum creatinine, measured or estimated creatinine creatinine pool. In two patients with differing creatinine pools (determined mainly by gender, age and weight) clearance, or as time to doubling of serum creatinine. The slope methods gives an absolute rate of loss of a doubling from the same baseline creatinine level, corresponds to different changes in GFR. Furthermore renal function per time and is based on the assumption of a linear decline in renal function. Using time to it can only be considered relevant, if a reasonable fraction of the patients reach the endpoint within the doubling of serum creatinine, it is not necessary to assume the decline to be linear. Although this assump-follow up period. Otherwise there is a large probability of a type 2 error, a false negative outcome. This tion of linearity is often made and several studies support this, it has not been proven to be the case in problem was illustrated by the study of the effect of angiotensin converting enzyme inhibition on diabetic all kidney diseases. In contrast using time to doubling of serum creatinine gives a relative expression of pro-nephropathy by the collaborative study group [3] . The study included 409 patients with diabetic nephropathy. gression. If the decline is linear, then the time to doubling of serum creatinine will become less with The patients were followed for a median of 3 years (range 1.8-4.8) , and were randomized to either captopdecreasing GFR, thus it is necessary with similar baseline levels of creatinine to make a comparison of ril or placebo in addition to the usual antihypertensive medication. Sixteen per cent of the patients progressed time to doubling of serum creatinine between groups.
From a statistical point of view there are several to the end point, i.e. doubling of baseline serum creatinine. A significant reduction in the risk of doubadvantages of using time to doubling of serum creatinine instead of the slope of GFR with time, apart from ling of baseline serum creatinine was found overall, but in a subgroup analysis this was not significant in avoiding the assumption of linearity. It takes several measurements over a period of time, preferentially 307 patients with normal serum creatinine at baseline (<1.5 mg/dl ). It is possible that angiotensin converting years, to establish the slope in GFR. Patients dropping out of a study after shorter periods of follow up are enzyme inhibition has a specific renoprotective effect, beyond lowering of blood pressure, only at certain thus not eligible for evaluation, in contrast all patients with at least two measurements of serum creatinine stages in the development of diabetic kidney disease, i.e. microalbuminuria and severely impaired renal funcare eligible in an analysis of time to doubling of serum creatinine.
tion. It is also very likely, however, that in the groups with normal serum creatinine levels the number of When using time to event, such as doubling of serum creatinine, as an endpoint, the methods used to analyse events were too small, making it impossible to detect any potential differences between the groups. A presurvival data can be applied. This allows the presentation of results using easily understandable survival study power calculation should be carried out taking the level of renal function and the expected progression curves. Confounding variables can be controlled for by using for example Cox regression analysis, which rate into consideration. also takes care of drop outs by censoring. Confounders and drop-outs can also be controlled for when applying Conclusion slope analysis models, although it requires less simple methods [8] .
However, in many studies only a small fraction of The use of time to doubling of serum creatinine as an endpoint in intervention trials aiming at reducing the the patients reaches the endpoint, i.e. doubling of creatinine. These may be 'fast trackers', a subgroup rate of progression in chronic renal disease is cheap, and convenient both for the patient and in the statistwith fast progression, having an increased risk of being confounded with different renal diseases. It is also ical analysis. The specificity is high, when a confounding effect of the intervention can be excluded, possible that the effect of intervention is different in 'fast trackers' compared to 'slow trackers'. The dicho-and when other factors such as changes in protein intake, muscle mass and concomitant medication, are tomous endpoint 'doubling of serum creatinine' will not evaluate potential changes within the group of taken into consideration. Unfortunately the sensitivity is low, particularly in patients with normal renal func-'slow trackers', unless they are followed until reaching Prospective, randomised, multicentre trial of effect of protein tion, and the endpoint is only relevant when a sufficient restriction on progression of chronic renal insufficiency. Lancet number of events can be expected, i.e. in studies of 1991; 337: 1299-1304 advanced and fast progressing chronic renal disease. 
